SAB BIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced that management will participate in two investor conferences in February 2026: Guggenheim Securities Emerging Outlook: Biotech Summit on February 11, 2026 (10:30 a.m. ET, New York) and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 (8:40 a.m. ET, virtual).

According to the company, both appearances include fireside chats and will be available live and on demand via the Investors & Media section of the company website at www.sab.bio.

News Market Reaction

-4.94%

1 alert

-4.94% News Effect

On the day this news was published, SABS declined 4.94%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences in February:

Guggenheim Securities Emerging Outlook: Biotech Summit
Date: February 11, 2026
Time: 10:30 a.m. ET
Format: Fireside Chat
Location: New York, NY

Oppenheimer 36^th Annual Healthcare Life Sciences Conference
Date: February 25, 2026
Time: 8:40 a.m. ET
Format: Fireside Chat
Location: Virtual

To access a live webcast of these events, as well as an archived recording, please visit the Investors & Media section of the Company’s website at www.sab.bio.  

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.

CONTACTS
Investors:
Cristi Barnett
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

FAQ

When will SAB Biotherapeutics (SABS) present at the Guggenheim Emerging Outlook: Biotech Summit?

SAB Biotherapeutics will present on February 11, 2026 at 10:30 a.m. ET in New York. According to the company, the management appearance is a fireside chat and will be webcast live with an archived recording available on www.sab.bio.

What is the date and format for SAB Biotherapeutics (SABS) at the Oppenheimer Healthcare Life Sciences Conference?

SAB Biotherapeutics will participate on February 25, 2026 at 8:40 a.m. ET in a virtual fireside chat. According to the company, the session will be accessible via a live webcast and later as an archived recording on its investor website.

How can investors watch the SABS presentations and archived webcasts for February 2026 conferences?

Investors can watch the live webcasts and archived recordings on the company’s investor site at www.sab.bio. According to the company, both the Guggenheim and Oppenheimer appearances will be posted in the Investors & Media section for on-demand access.

Will SAB Biotherapeutics (SABS) discuss its hATG program for type 1 diabetes at the February 2026 conferences?

The company will present management commentary during fireside chats at both events, where program updates may be discussed. According to the company, investors should view the live webcasts or archived recordings on www.sab.bio for specific program details.

What times should investors note for SAB Biotherapeutics (SABS) February 2026 investor events?

Key times are 10:30 a.m. ET on February 11, 2026 and 8:40 a.m. ET on February 25, 2026. According to the company, both sessions are fireside chats and will be webcast live with archives available on its investor website.